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Abstract
Background: The intermediate filament protein vimentin undergoes reversible phosphorylation and
dephosphorylation at Ser-56, which plays an important role in regulating the contraction-relaxation cycles of
smooth muscle. The protein phosphatases that mediate vimentin dephosphorylation in smooth muscle have
not been previously investigated.
Methods: The associations of protein phosphatase 1 (PP1) and protein phosphatase 2A (PP2A) with vimentin in
mouse tracheal rings was evaluated by co-immunoprecipitation. Lentivirus-mediated shRNA against PP1 was used to
assess the role of PP1 in vimentin dephosphorylation and the vimentin-associated process in smooth muscle.
Results: Co-immunoprecipitation analysis showed that vimentin interacted with PP1, but barely with PP2A, in airway
smooth muscle. Knockdown of PP1 by lentivirus-mediated shRNA increased the acetylcholine-induced vimentin
phosphorylation and smooth muscle contraction. Because vimentin phosphorylation is able to modulate p130
Crk-associated substrate (p130CAS) and actin polymerization, we also evaluated the role of PP1 in the
biological processes. Silencing of PP1 also enhanced the agonist-induced the dissociation of p130CAS from
vimentin and F/G-actin ratios (an index of actin polymerization). However, PP1 knockdown did not affect c-Abl tyrosine
phosphorylation, an important molecule that controls actin dynamics.
Conclusions: Taken together, these findings suggest that PP1 is a key protein serine/threonine phosphatase that
controls vimentin Ser-56 dephosphorylation in smooth muscle. PP1 regulates actin polymerization by modulating the
dissociation of p130CAS from vimentin, but not by affecting c-Abl tyrosine kinase.
Background
The vimentin intermediate filament network of fully dif-
ferentiated smooth muscle connects with the desmo-
some on the cellular membrane and links to the dense
bodies in the myoplasm, which enables vimentin fila-
ments to mediate the intercellular and intracellular force
transmission in smooth muscle [1–5]. Vimentin under-
goes phosphorylation at Ser-56 in a variety of cells/tis-
sues in response to changes in environment, which plays
a role in regulating various cellular functions including
smooth muscle contraction [4–9]. Vimentin phosphoryl-
ation at Ser-56 regulates vimentin depolymerization and
the spatial reorientation of vimentin filaments, which
modulates the intercellular force transmission and con-
traction in smooth muscle [2–5, 9–15].
Vimentin phosphorylation at Ser-56 is regulated by
p21-activated kinase 1 (PAK1) in smooth muscle. Con-
tractile stimulation of smooth muscle induces PAK1
phosphorylation at Thr-423, an indication of PAK1 acti-
vation [4, 5, 9, 16]. PAK1 knockdown inhibits vimentin
phosphorylation at this residue in response to contractile
activation [4, 5, 9, 16]. PAK1 is able to directly catalyze
vimentin phosphorylation as evidenced by the in vitro
kinase assay [9, 16]. Vimentin phosphorylation at Ser-56
may be also mediated by other kinases. For example,
Cdk5 mediates vimentin Ser-56 phosphorylation during
GTP-induced secretion by neutrophils [6].
Smooth muscle contraction is dependent upon actin
filament polymerization. A pool of actin monomers is
added onto existing actin filaments in smooth muscle in
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response to contractile activation [17–23]. Inhibition of
actin filament polymerization by pharmacological inhibi-
tors or molecular approaches attenuates smooth muscle
contraction with little or no inhibition of myosin light
chain (MLC) phosphorylation [12, 17, 24–26]. Actin fila-
ment polymerization may promote contraction by enhan-
cing the force transmission between the contractile units
and the extracellular matrix [12, 24, 26, 27], by increasing
numbers of the contractile units [12, 18, 24–26], and by
strengthening the cadherin complex [27, 28]. Actin dy-
namics in smooth muscle is regulated in part by c-Abl
tyrosine kinase [21, 22, 27, 29, 30]. In addition, vimentin
phosphorylation also regulates actin polymerization by af-
fecting the interaction of p130CAS (p130 Crk-associated
substrate) with vimentin [4, 5, 9, 31].
MLC phosphorylation at Ser-19 is an important aspect
of the cellular mechanisms that regulate smooth muscle
contraction. MLC phosphorylation at Ser-19 increases
myosin ATPase activity and initiates crossbridge cycling
and force generation [32, 33]. The level of MLC phos-
phorylation at Ser-19 is regulated by myosin light chain
kinase and myosin light chain phosphatase [34, 35].
Protein phosphatase 1 (PP1) and protein phosphatase
2A (PP2A) have been implicated in smooth muscle con-
traction [36, 37]. PP1 and PP2A serve as catalytic sub-
units and interact with other regulatory subunits
(cofactors) to form holoenzymes for specific substrate
dephosphorylation. The best characterized protein phos-
phatase in smooth muscle is MLC phosphatase, which
consists of PP1, a regulatory subunit (MYPT1) and a 20-
KDa subunit (M20) with unknown function [38]. MLC
phosphatase dephosphorylates MLC phosphorylation at
Ser-19 and may be regulated during contractile activation
of smooth muscle [35, 38]. PP2A in smooth muscle has
been implicated in dephosphorylating several substrates
including L-type Ca2+ channel, BKca channel, PKC, caldes-
mon and calponin [36]. However, the phosphatases that
mediate vimentin Ser-56 dephosphorylation in smooth
muscle have not been previously investigated.
The objective of this study was to assess whether PP1
and/or PP2A have a role in vimentin dephosphorylation
at Ser-56 in airway smooth muscle. We used mouse tra-
cheal rings to investigate airway smooth muscle biology
because the physiological and biochemical properties of
the tissue preparations are similar to human airway
smooth muscle [20, 29, 39]. Our results suggest that PP1
mediates vimentin dephosphorylation at this position
during contractile activation of smooth muscle.
Methods
Animals
All experimental protocols were approved by the In-
stitutional Animal Care and Usage Committee (Animal
Welfare Assurance Number A3099-01). C57BL/6 mice
(25 ± 5 g, 8–12 weeks old) were originally purchased from
Taconic Biosciences and bred in the specific pathogen free
housing of Animal Research Facility, Albany Medical
College. The animal housing was kept at 21–22 °C
with 45–55 relative humidity. The light/dark cycle of
the housing was 7 am- 7 pm for fluorescent/LED
lights and 7 pm – 7 am for red lights. The numbers
of cage companions were 3–8 each based on animal
ages and gender. Animals were healthy and able to
breed normally. They were fed with Purina Lab Diet
5P76 and had continuous access to food and water.
Both male and female mice were randomized allocated to
the experimental or control groups. The experimental unit
represented each trachea from individual animals.
Measurement of tracheal ring contraction
Animals were sacrificed with overdosed pentobarbital
sodium (100 mg/kg). Tracheal rings (4–5 mm long) were
immediately removed and placed at room temperature
in physiological saline solution (PSS) containing
110 mM NaCl, 3.4 mM KCl, 2.4 mM CaCl2, 0.8 mM
MgSO4, 25.8 mM NaHCO3, 1.2 mM KH2PO4, and
5.6 mM glucose. The solution was aerated with 95 %
O2-5 % CO2 to maintain a pH of 7.4. Tracheal rings
were then placed in PSS at 37 °C in a 25-ml organ bath
and attached to a Grass force transducer that had been
connected to a Gould recorder or a computer with A/D
converter (Grass). At the beginning of each experiment,
0.5 g passive tension was applied to tracheal rings. After
60 min equilibrium they were stimulated with 80 mM
KCl repeatedly until contractile responses and passive
tension reached a steady state.
For lentivirus-mediated shRNA in tissues, the thin
epithelium layer of tracheal rings was removed by
using forceps. They were then transduced with lenti-
virus encoding pan PP1 shRNA (sc-43533-V, Santa
Cruz Biotechnology) or viruses for control shRNA
(sc-108080, Santa Cruz Biotechnology) for 4 days.
Contraction in response to agonist activation was
compared before and after lentivirus transduction. For
biochemical analysis, tissues were frozen using liquid
nitrogen and pulverized as previously described [3, 4, 21].
Immunoblot analysis
Pulverized tissues were lysed in SDS sample buffer com-
posed of 1.5 % dithiothreitol, 2 % SDS, 80 mM Tris–HCl
(pH 6.8), 10 % glycerol, 0.01 % bromophenol blue, phos-
phatase inhibitors (2 mM sodium orthovanadate, 2 mM
molybdate, and 2 mM sodium pyrophosphate) and pro-
tease inhibitors (2 mM benzamidine, 0.5 mM aprotinin
and 1 mM phenylmethylsulfonyl fluoride). The lysates
were boiled in the buffer for 5 min and separated by
SDS-PAGE. Proteins were transferred to a nitrocellulose
membrane. The membrane was treated with blockers for
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1 h and probed with use of primary antibody followed
by horseradish peroxidase-conjugated secondary antibody
(Fisher Scientific). Proteins were visualized by enhanced
chemiluminescence (Fisher Scientific) using the LAS 400
Fuji imaging system or GE Amersham Imager 600 system.
Antibodies against PP1, PP2A, phospho-myosin light
chain (Ser-19), myosin light chain, phospho-c-Abl
(Tyr-412) and pan c-Abl were purchased from Santa
Cruz Biotechnology. Glyceraldehyde 3-phosphate de-
hydrogenase (GAPDH) antibody was purchased from
Fitzgerald (MA, USA). Antibodies against vimentin
and p130CAS were obtained from BD Biosciences.
Phospho-vimentin (Ser-56) antibody was custom made
by our laboratory as previously described [4, 9, 16].
Antibody against α-actin was acquired from Sigma-
Aldrich. The levels of proteins were quantified by scanning
densitometry of immunoblots (Fuji Multigauge Software or
GE IQTL software). The luminescent signals from all im-
munoblots were within the linear range [20, 21, 28, 40, 41].
Co-immunoprecipitation analysis
Co-immunoprecipitation analysis was used to evaluate
protein-protein interactions as previously described
[9, 20, 22]. Briefly, tissue extracts were incubated
overnight with corresponding antibodies and then in-
cubated for 2–3 h with 125 μl of a 10 % suspension
of protein A-Sepharose beads. Immunocomplexes
were washed four times in buffer containing 50 mM
Tris–HCl (pH 7.6), 150 mM NaCl and 0.1 % Triton
X-100. The immunoprecipitates were separated by
SDS-PAGE followed by transfer to nitrocellulose
membranes. The membranes of immunoprecipitates
were probed with corresponding antibodies.
Analysis of p130CAS dissociation with cytoskeletal
vimentin
Cytoskeletal vimentin was collected using the method as
previously described [4, 9, 10, 16, 31]. Briefly, tissues
were homogenized in buffer containing 1 % Nonidet P-
40, 10 % glycerol, 20 mM Hepes, pH 7.6, 150 mM NaCl,
2 mM sodium orthovanadate, 2 mM molybdate, 2 mM
sodium pyrophosphate and protease inhibitors (2 mM
benzamidine, 0.5 mM aprotinin and 1 mM phenyl-
methylsulfonyl fluoride). The homogenates were imme-
diately incubated in the same buffer at 37 °C for 30 min.
The soluble (depolymerized) and insoluble (cytoskeletal)
fractions were separated after centrifugation at
5,200 rpm, 4 °C for 30 min. The equal amount of cyto-
skeletal vimentin was separated by 10 % SDS-PAGE, and
was transferred to nitrocellulose membranes. The mem-
branes were cut into two parts; the upper part was
probed with monoclonal p130CAS antibody. The lower
part of the membrane was blotted with vimentin
antibody. The ratio of p130CAS to vimentin was calcu-
lated after densitometrical analysis of immunoblots.
Analysis of F-actin/G-actin ratios
The content of F-actin and G-actin in smooth muscle
was measured using a method as previously described
[21, 22]. Briefly, tissues were treated with F-actin
stabilization buffer (50 mM PIPES, pH 6.9, 50 mM NaCl,
5 mM MgCl2, 5 mM EGTA, 5 % glycerol, 0.1 % Triton
X-100, 0.1 % Nonidet P40, 0.1 % Tween 20, 0.1 % beta-
mercapto-ethanol, 1 mM ATP, 1 μg/ml pepstatin, 1 μg/
ml leupeptin, 10 μg/ml benzamidine). The supernatants
of protein extracts were collected after centrifugation at
151,000 g for 60 min at 37 °C. The pellets were resus-
pended in ice-cold H2O plus 1 μM cytochalasin D and
then incubated on ice for 1 h to dissociate F-actin. The
resuspended pellets were gently mixed every 15 min.
The supernatant of the resuspended pellets was collected
after centrifugation at 16,100 g for 2 min at 4 °C. Equal
volume of the first supernatant (G-actin) or second
supernatant (F-actin) was subjected to immunoblot ana-
lysis using α-smooth muscle actin antibody (Sigma). The
amount of F-actin and G-actin was determined by scan-
ning densitometry.
Statistical analysis
All statistical analysis was performed using Prism 6 soft-
ware (Graphpad Software Inc., CA). Differences between
pairs of groups were analyzed by Student-Newman-
Keuls test or Dunn’s method. Values of n refer to the
number of experiments used to obtain each value. P <
0.05 was considered to be significant. PS: Power and
Sample Size Calculation software (Vanderbilt University)
was used to determine the sample size.
Results
Treatment with okadaic acid induces airway smooth
muscle contraction
Although protein phosphatases have been implicated
in vascular and uterine smooth muscle contraction
[36, 37], the role of protein phosphatases in airway
smooth muscle is not well elucidated. Mouse tracheal
rings were treated with okadaic acid, a potent PP1
and 2A inhibitor [36, 37]. Contractile responses were then
measured using a muscle research system [4, 5, 20, 28, 29,
31]. A representative force tracing after treatment with
okadaic acid was shown in Fig. 1a. Treatment with oka-
daic acid induced mouse tracheal smooth muscle contrac-
tion, which was dose-dependent (Fig. 1b). However,
treatment with okadaic acid did not affect the ACh-
induced contraction (Fig. 1a). The results suggest that the
inhibition of PP1 and/or PP2A induces airway smooth
muscle contraction, but not sensitize the precontracted
smooth muscle.
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Treatment with okadaic acid increases vimentin
phosphorylation at Ser-56 in smooth muscle tissues
Previous studies suggest that vimentin phosphorylation
at Ser-56 is critical for smooth muscle contraction [3–5,
9, 12, 27]. Vimentin phosphorylation at this position reg-
ulates smooth muscle contraction by inducing the redis-
tribution of signaling molecules and the spatial
reorientation of the vimentin network [3–5, 9]. Further-
more, vimentin phosphorylation at Ser-56 is catalyzed by
PAK1 [4, 5, 9, 12, 16]. However, it is currently unknown
which phosphatases mediate vimentin Ser-56 dephosphor-
ylation in smooth muscle. Mouse tracheal smooth muscle
tissues were treated with okadaic acid for 1–10 min.
Vimentin phosphorylation at Ser-56 and contraction were
then evaluated. Treatment with okadaic acid induced
vimentin phosphorylation at Ser-56 (Fig. 1c), which was
coordinately associated with an increase in smooth muscle
contraction (Fig. 1d). These results suggest that PP1 and/
Fig. 1 Inhibition of protein phosphatases 1 and 2A induces contraction and vimentin phosphorylation at Ser-56 in airway smooth muscle.
a Upper panel: A representative force tracing illustrating the effects of okadaic acid (OA), a potent inhibitor of protein phosphatase 1 (PP1) and protein
phosphatase 2A (PP2A) on mouse tracheal rings. Lower panel: A representative force tracing showing the effects of okadaic acid on the precontracted
mouse tracheal rings. b Mouse tracheal rings were treated with different concentrations of okadaic acid. Contraction in these tissues was
then evaluated. Tracheal contraction is normalized to the maximal contraction induced by okadaic acid. Data represent mean ± SE (n = 5).
**, p < 0.01 vs. untreated tissues. c Mouse tracheal rings were treated with 10−6M okadaic acid for 1 – 10 min. Vimentin phosphorylation at Ser-56 in
tissues was evaluated by immunoblot analysis. OA-induced vimentin phosphorylation is normalized to the value of untreated tissues. Vimentin
phosphorylation is significantly higher in rings treated with okadaic acid than in untreated rings (*, p < 0.05). Data represent mean ± SE (n = 7–11).
d Contraction is normalized to the maximal contraction induced by okadaic acid (10−6 M, 10 min). Data represent mean ± SE (n = 7–11). *, p < 0.05 vs.
untreated tissues
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or PP2A may mediate vimentin dephosphorylation at this
position in airway smooth muscle.
Contractile activation induces the dissociation of PP1
from vimentin in smooth muscle tissues
To assess the role of PP1 and/or PP2A, we evaluated the
interaction of the phosphatases with vimentin. Smooth
muscle tissues were stimulated with acetylcholine (ACh),
or left unstimulated. Extracts of these tissues were
immunoprecipitated with vimentin antibody and immu-
noblotted with antibodies against vimentin, PP1 or PP2A.
In unstimulated tissues, PP1 was detected in vimentin
immunoprecipitates. Upon stimulation with ACh, the
ratios of PP1 over vimentin immunoprecipitates were
reduced as compared to unstimulated tissues (Fig. 2a).
However, PP2A was barely found in the precipitates.
Moreover, the ratios of PP2A/vimentin were not signifi-
cantly affected by contractile stimulation (Fig. 2b). The re-
sults suggest that vimentin predominantly interacts with
PP1 in unstimulated smooth muscle. Contractile activation
induces the dissociation of PP1 from vimentin in smooth
muscle. We conclude that PP1 is likely a candidate for
vimentin Ser-56 dephosphorylation in smooth muscle.
Knockdown of PP1 increases vimentin phosphorylation at
ser-56 and smooth muscle contraction
To determine the role of PP1, we utilized a lentivirus-
mediated shRNA approach [19–21, 28, 41] to inhibit the
expression of PP1. Contractile response of mouse tra-
cheal rings to ACh was evaluated. The rings were then
transduced with lentiviruses encoding control shRNA or
PP1 shRNA. These tissues were incubated in the
medium for 4 days. Immunoblot analysis verified the
lower expression of PP1 in tissues transduced with
viruses encoding PP1 shRNA compared to tissues trans-
duced with viruses for control shRNA (Fig. 3a).
We then evaluated vimentin phosphorylation at Ser-56
in these tissues. Compared to tissues expressing control
shRNA, basal vimentin phosphorylation at Ser-56 was
not significantly altered in tissues expressing PP1
shRNA. More importantly, ACh-induced vimentin phos-
phorylation at Ser-56 was higher in PP1-deficient tissues
than in tissues expressing control shRNA (Fig. 3b). We
also determined the effects of PP1 knockdown on
smooth muscle contraction. In tissues treated with lenti-
virus expressing control shRNA, ACh stimulation was able
to stimulate contractile response. Moreover, contraction in
Fig. 2 Contractile activation induces the dissociation of PP1, but not PP2A, from vimentin in smooth muscle. a Representative immunoblots
illustrating the interaction of PP1 with vimentin. Mouse tracheal rings were stimulated with acetylcholine (ACh, 10−4 M, 5 min) or left
unstimulated. Extracts of these tissues were immunoprecipitated using vimentin antibody, and blotted with use of antibodies against PP1
and vimentin. PP1 antibody, but not IgG, immunoprecipitates PP1 and vimentin. The ratios of PP1 to vimentin in the ACh-treated tissues
are normalized to those in untreated tissues. *Significantly lower ratio of PP1/vimentin in ACh-treated rings as compared to untreated tissues (p < 0.05).
Data are mean ± SE (n = 5). b Extracts of tissues treated with or without ACh (10−4 M, 5 min) were immunoprecipitated with vimentin antibody, and
blotted with use of antibodies against PP2A and vimentin. PP2A is barely present in vimentin immunoprecipitates. The ratios of PP2A to vimentin in
the ACh-treated tissues are normalized to those in untreated tissues. N.S., not significant (p < 0.05). Data are mean ± SE (n = 5)
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PP1-deficient tissues was higher as compared to tissues ex-
pressing control shRNA (Fig. 3c). Passive tension in PP1-
deficient tissues was slightly increased. We conclude that
PP1 mediates vimentin dephosphorylation at Ser-56 and
inhibits smooth muscle contraction.
PP1 regulates disassociation of p130CAS from
cytoskeletal vimentin in smooth muscle
Our previous studies have shown that vimentin phos-
phorylation enhances the disengagement of p130CAS
from vimentin, which may promote smooth muscle con-
traction [3–5, 10, 11]. We determined the effects of oka-
daic acid on the association of p130CAS with vimentin.
Cytoskeletal vimentin for smooth muscle tissues was
collected using the intermediate filament fractionation
assay [4, 5, 9, 31]. The equal amount of cytoskeletal
vimentin was separated by SDS-PAGE and immuno-
blotted with antibodies against vimentin and p130CAS.
In tissues not treated with okadaic acid, the amount of
p130CAS was relatively higher. In contrast, the amount
of p130CAS in cytoskeletal vimentin was reduced in
rings treated with okadaic acid. The ratios of p130CAS/
vimentin were reduced upon treatment with okadaic
acid (Fig. 4a).
We also assessed the effects of PP1 knockdown on the
interaction of p130CAS with vimentin. Compared to tis-
sues expressing control shRNA, the amount of p130CAS
in the vimentin fraction was lower in PP1-deficient tis-
sues during ACh stimulation (Fig. 4b). Taken together,
we conclude that PP1 is able to inhibit the disassociation
of p130CAS from the vimentin cytoskeleton.
Actin dynamics is regulated by PP1 in smooth muscle in
response to contractile activation
It is well recognized that smooth muscle contraction is
regulated by actin filament polymerization [12, 24, 26, 27].
Because PP1 is able to regulate smooth muscle force de-
velopment, this raises a possibility that PP1 may modulate
actin dynamics. To test this, we assessed the effects of PP1
knockdown on actin polymerization by using the actin
fractionation assay [20–22, 28]. In tissues treated with
control shRNA, ACh stimulation was able to increase
F/G-actin ratios, an indication of actin polymerization
[20, 24]. Furthermore, the ACh-induced increases in
F/G-actin ratios were higher in PP1-deficient tissues
than in tissues expressing control shRNA (Fig. 5a).
The results suggest that PP1 inhibits the agonist-
induced actin filament assembly in smooth muscle.
Phosphorylation of c-Abl tyrosine kinase is not affected
by PP1
c-Abl is a nonreceptor protein tyrosine kinase that regu-
lates actin dynamics and smooth muscle contraction [21,
22, 27, 29, 30]. Since PP1 silencing affects actin filament
polymerization, we questioned whether PP1 has a role in
regulating c-Abl tyrosine kinase. Tissues expressing con-
trol shRNA and PP1-deficient tissues were stimulated
with ACh, or left unstimulated. c-Abl phosphorylation at
Tyr-412, an indication of c-Abl activation [12, 22, 24,
27], in these tissues was evaluated by immunoblot ana-
lysis. The ACh-induced c-Abl tyrosine phosphorylation
in PP1-deficient tissues was similar to that in tissues
expressing control shRNA. In addition, basal c-Abl
Fig. 3 Knockdown of PP1 increases vimentin phosphorylation at Ser-56 and contraction in smooth muscle. a Mouse tracheal rings were transduced
with lentiviruses encoding control shRNA or PP1 shRNA. These tissues were then incubated in the serum-free medium for 4 days. Immunoblot analysis
was used to assess protein expression in tissues. Ctrl, control shRNA; PP1, PP1shRNA. *Significantly lower protein ratios of PP1/actin in
tissues transduced with virus encoding PP1 shRNA than in tissues expressing control shRNA (p < 0.05). Data represent mean ± SE (n = 5).
b Tracheal rings treated with control or PP1 shRNA were stimulated with ACh (10−4 M, 5 min), or left unstimulated. Vimentin phosphorylation at Ser-56
was evaluated by immunoblotting. Vimentin phosphorylation is normalized to unstimulated rings treated with control shRNA. Data are
mean values of eight independent experiments. Error bars indicate SE (*, p < 0.05). c Contraction of tracheal rings was evaluated, after
which they were transduced with lentiviruses as described above. Contractile responses were compared before and after incubation. Contraction is
normalized to the contraction of rings treated with control shRNA in response to stimulation with 10−3 M ACh. *Significantly higher contraction of
rings treated with PP1 shRNA as compared to tissues infected with viruses encoding control shRNA (p < 0.05). Data are mean ± SE (n = 6)
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phosphorylation was not affected by PP1 knockdown
(Fig. 5b). We conclude that PP1 is not involved in the
phosphorylation of c-Abl tyrosine kinase.
PP1 regulates dephosphorylation of myosin light chain
phosphorylation at ser-19
Because myosin light chain phosphorylation at Ser-19 is
one of the major cellular processes in smooth muscle in
response to agonist stimulation [32–35], we determined
the effects of PP1 knockdown on myosin light chain
phosphorylation. Compared to tissues expressing control
shRNA, myosin light chain phosphorylation at Ser-19
upon ACh stimulation was higher in PP1- deficient tis-
sues (Fig. 6). Knockdown of PP1 did not significantly
affect myosin light chain phosphorylation without ACh
stimulation (Fig. 6).
Since PP1 knockdown enhances the ACh-induced
vimentin phosphorylation at Ser-56 (Fig. 3b), myosin
Fig. 4 Dissociation of p130CAS from vimentin is regulated by PP1. a Equal amount of insoluble vimentin from untreated and okadaic acid (OA,
10−6 M)-treated tracheal rings were separated by SDS-PAGE, and transferred to nitrocellulose membranes. The membranes were probed with use
of p130CAS antibody and vimentin antibody. The ratios of p130CAS to vimentin in the OA-treated tissues are normalized to those in untreated
tissues. *Significantly lower ratio of p130CAS/vimentin in treated rings as compared to untreated tissues (p < 0.05). Data are mean ± SE (n = 5).
b Tracheal tissues expressing control (Ctrl) or PP1 shRNA were stimulated with 10−4 M ACh for 5 min. The ratios of p130CAS/vimentin in tissues
treated with PP1 shRNA are normalized to the ratios in tissues treated with control shRNA. Data are mean ± SE (n = 4). *,p < 0.05
Fig. 5 PP1 modulates ACh-induced actin polymerization, but not phosphorylation of c-Abl tyrosine kinase. a Tracheal rings treated with control
(Ctrl) or PP1 shRNA were stimulated with 10−4 M ACh for 5 min, or left unstimulated. F/G-actin ratios in the tissues were evaluated using the actin
fractionation assay. The ratios of F/G-actin under various treatments are normalized to the ratios in unstimulated tissues treated with control
shRNA. Data are mean ± SE (n = 7). *, p < 0.05. b c-Abl phosphorylation at Tyr-412 in tissues treated with control or PP1 shRNA in the presence or
absence of ACh was assessed by immunoblot analysis. c-Abl phosphorylation is normalized to the values in unstimulated rings treated with control
shRNA. Data are mean ± SE (n = 4). N.S., not significant
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light chain phosphorylation (Fig. 6) and contraction
(Fig. 3c), it is likely that PP1 regulates smooth muscle
contraction by controlling both the vimentin-associated
pathway and myosin light chain-associated pathway.
Discussion
The intermediate filament protein vimentin gets phos-
phorylated at Ser-56 in cells/tissues in response to
changes in external environment, which has a role in
regulating various cellular functions including smooth
muscle contraction [4–9]. PAK1 has been implicated in
promoting vimentin phosphorylation at Ser-56 in smooth
muscle [4, 5, 9, 16]. The nature of protein serine/threonine
phosphatases that mediate vimentin dephosphorylation in
smooth muscle has not been previously described.
Treatment with the PP1 and PP2A inhibitors okadaic
acid and calyculin A induced vimentin phosphorylation
at Ser-71 in NIH3T3 cells. But, 10–20 nM calyculin A
was able to induce vimentin phosphorylation at Ser-71
whereas higher doses (3–10 μM) of okadaic acid were
required to induce vimentin phosphorylation. Because
okadaic acid and calyculin A inhibit PP2A with similar
potency, the authors concluded that PP1 is a major pro-
tein phosphatase that mediates vimentin phosphoryl-
ation at Ser-71 [42]. In contrast, treatment with okadaic
acid, but not tautomysin (a putative PP1 inhibitor) in-
duced vimentin phosphorylation in human Hs68 fibro-
blasts [43]. The authors concluded that PP2A, but not
PP1, dephosphorylates vimentin in these cells [43]. In
this report, we also observe that treatment with okadaic
acid increases vimentin phosphorylation at Ser-56 in
smooth muscle. Because the inhibitors are not specific,
we also used lentivirus-mediated shRNA against PP1to
specifically downregulates PP1 expression. PP1 knock-
down enhances the agonist-induced vimentin Ser-56
phosphorylation. Our results suggest that PP1 is a pre-
dominant protein serine/threonine phosphatase that me-
diates vimentin dephosphorylation at Ser-56 in smooth
muscle. To the best of our knowledge, this is the first evi-
dence to suggest that PP1 controls vimentin dephosphory-
lation in smooth muscle. However, we do not rule out the
possibility that PP2A may mediate vimentin dephosphory-
lation at other residues or in nonmuscle cell types.
Relatively few protein serine/threonine phosphatases
regulate the dephosphorylation of thousands of phospho-
protein substrates. Typically, protein phosphatases such as
PP1 and PP2A serve as catalytic subunits and interact
with other cofactors to achieve specific substrate dephos-
phorylation. In smooth muscle, MLC phosphatase is com-
prised of PP1, MYPT1 and a 20-KDa subunit (M20) with
unknown function. MYPT1 is able to interact with myosin
light chain and renders MLC phosphatase specific. In
addition, MYPT1 also regulates the functional state of
MLC phosphatase [38]. We believe that the potential
vimentin phosphatase (holoenzyme) should consist of PP1
and a regulatory subunit (a cofactor) at least. Future stud-
ies are required to identify the potential regulatory subunit
of vimentin phosphatase.
In smooth muscle, the activity of MLC phosphatase is
regulated by MYPT1 phosphorylation at Thr-696 and/or
Thr-853 in vascular, gastrointestinal and myometrial
smooth muscle [36]. Phosphorylation of these residues
may inhibit the activity of MLC phosphatase, which
increases MLC phosphorylation at Ser-19 and smooth
muscle contraction [35, 36]. In this study, contractile
activation induces the dissociation of PP1 with vimentin.
Furthermore, agonist stimulation also results in an
increase in vimentin phosphorylation at Ser-56 and con-
traction. The results indicate that PP1 activity may be
regulated in smooth muscle in response to contractile
activation. It is likely that contractile activation may in-
hibit PP1 activity, and/or results in the dissociation of
PP1 from vimentin, which enhances vimentin phosphor-
ylation at Ser-56 and smooth muscle contraction.
Both vimentin phosphorylation at Ser-56 and actin
polymerization participate in the regulation of smooth
muscle contraction. There is crosstalk between the
vimentin network and the actin cytoskeleton [5, 12, 27].
Vimentin phosphorylation at Ser-56 is capable of regu-
lating the interaction of p130CAS with the vimentin
cytoskeleton. p130CAS is an adapter protein that pro-
motes actin polymerization by activating the N-WASP/
Arp2/3 pathway [4, 5, 22, 26, 44]. In unstimulated
Fig. 6 PP1 regulates myosin light chain phosphorylation at Ser-19 in
smooth muscle. Mouse tracheal rings treated with control (Ctrl) or PP1
shRNA were stimulated with 10−4 M ACh for 5 min, or left unstimulated.
Myosin light chain (MLC) phosphorylation at Ser-19 in the tissues was
evaluated by immunoblot analysis. MLC phosphorylation under various
treatments is normalized to the phosphorylation in unstimulated tissues
treated with control shRNA. Data are mean ± SE (n = 4). *, p< 0.05
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smooth muscle, approximately 50 % of total p130CAS
interacts with cytoskeletal vimentin, which hinders the
p130CAS-mediated actin polymerization. Upon con-
tractile stimulation, vimentin undergoes phosphorylation
at Ser-56, which releases p130CAS from the vimentin
cytoskeleton and provides more “free” p130CAS for
actin polymerization [4, 5, 9, 31]. In this study, knock-
down of PP1 increases the dissociation of p130CAS from
cytoskeletal vimentin and actin polymerization. Because
actin dynamics in smooth muscle is regulated in part by
c-Abl tyrosine kinase [21, 22, 27, 29, 30], we also
assessed the effects of PP1 silencing on c-Abl phosphor-
ylation. PP1 has no role in regulating c-Abl tyrosine
phosphorylation in smooth muscle upon contractile
stimulation. These results are consistent with the notion
that PP1 regulates vimentin dephosphorylation at Ser-
56, which in turn controls the association of p130CAS
with cytoskeletal vimentin and actin filament assembly
in smooth muscle during contractile activation.
PP1 and PP2A have been proposed to regulate smooth
muscle contraction by dephosphorylating contraction-
associated proteins [36, 37]. In smooth muscle, PP1 has
been proposed to regulate the dephosphorylation of my-
osin light chain, K+ channels and L-type Ca2+ channel
whereas PP2A has been implicated in dephosphorylating
several substrates including PKC, caldesmon and cal-
ponin [36]. Our present results suggest that PP1 is
able to mediate vimentin dephosphorylation at Ser-56
in addition to MLC dephosphorylation at Ser-19.
Thus, we propose that PP1 activity in smooth muscle
is attenuated in response to contractile stimulation,
which inhibits the dephosphorylation of phospho-
vimentin (Ser-56) and phospho-MLC (at Ser-19).
Vimentin phosphorylation may promote smooth
muscle contraction by increasing intercellular force
transmission [3, 5, 8, 9, 12] and p130CAS-mediated
actin polymerization [4, 5, 26, 27, 31, 45]. Myosin
phosphorylation may initiate crossbridge cycling and
myofilament sliding. Both vimentin phosphorylation
and myosin phosphorylation are needed for smooth
muscle contraction (Fig. 7).
Conclusions
Vimentin gets phosphorylated at Ser-56 in response to
contractile activation, which regulates smooth muscle
contraction. PAK1 has been shown to regulate vimentin
Ser-56 phosphorylation in smooth muscle. The protein
phosphatase that controls vimentin dephosphorylation
in smooth muscle has not been previously investigated.
Our present study reveals a new and novel role of PP1
in regulating vimentin dephosphorylation at this position
during contractile activation of smooth muscle, which
may regulate the interaction of p130CAS with cytoskel-
etal vimentin, actin polymerization and smooth muscle
contraction (Fig. 7).
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